NMO spectrum disorders: How wide is the spectrum?

Multiple Sclerosis

Volumn 20, Issue 10, 2014, Pages 1417-1419

  Arrambide, Georgina ^a   Rovira, Alex ^b   Tur, Carmen ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G; AQP4 PROTEIN, HUMAN; AUTOANTIBODY; BIOLOGICAL MARKER;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HIGH RISK PATIENT; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; MYELOOPTIC NEUROPATHY; MYOKYMIA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR NEUROMYOTONIA; PROGNOSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOPSY; BLOOD; CLASSIFICATION; DISEASE COURSE; IMMUNOLOGY; NEUROMYELITIS OPTICA; PREDICTIVE VALUE; SEROLOGY;

AQUAPORIN 4; AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN G; NEUROMYELITIS OPTICA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEROLOGIC TESTS;

EID: 84945251835     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514546517     Document Type: Note

References (30)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
2. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
3. Jarius S and Wildemann B. The history of neuromyelitis optica. J Neuroinflamm 2013; 10: 8
4. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261: 1-16.
5. Eichel R, Meiner Z, Abramsky O, et al. Acute disseminating encephalomyelitis in neuromyelitis optica: Closing the floodgates. Arch Neurol 2008; 65: 267-271.
6. Saiki S, Ueno Y, Moritani T, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci 2009; 284: 217-219.
7. Tasaki A, Shimizu F, Sano Y, et al. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2014; 85: 419-430.
8. Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 2008; 118: 218-225.
9. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
10. Nakajima H, Fujiki Y, Ito T, et al. Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Report Neurol 2011; 3: 263-267.
11. Nakano T, Fujimoto T, Fukuda Y, et al. Neuromyelitis optica with syndrome of inappropriate secretion of antidiuretic hormone and hypersomnia associated with bilateral hypothalamic lesions: A case report. Rinsho Shinkeigaku 2011; 51: 599-602.
12. You XF, Qin W and Hu WL. Aquaporin-4 antibody positive neuromyelitis optica with syndrome of inappropriate antidiuretic hormone secretion. Neurosciences (Riyadh) 2011; 16: 68-71.
13. Breningstall GN. An 11-year-old girl with syndrome of inappropriate antidiuretic hormone secretion. Semin Pediatr Neurol 1999; 6: 202-208.
14. Iorio R, Lucchinetti CF, Lennon VA, et al. Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. Neurology 2011; 77: 1644-1646.
15. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4expression. Arch Neurol 2006; 63: 964-968.
16. Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: A case report and literature review. Arch Neurol 2012; 69: 1355-1359.
17. Nishino S, Okuro M, Kotorii N, et al. Hypocretin/orexin and narcolepsy: New basic and clinical insights. Acta Physiol (Oxf) 2010; 198: 209-222.
18. Roper-Hall G, Chung SM and Cruz OA. Ocular neuromyotonia: Differential diagnosis and treatment. Strabismus 2013; 21: 131-136.
19. Park HY, Hwang JM and Kim JS. Abducens neuromyotonia due to internal carotid artery aneurysm. J Neurol Sci 2008; 270: 205-208.
20. Oohira A and Sonobe A. A case of Tolosa-Hunt syndrome presenting ocular neuromyotonia. Rinsho Shinkeigaku 2013; 53: 376-379.
21. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671.
22. Jarius S and Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. Brain Pathol 2013; 23: 661-683.
23. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-2082.
24. Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011; 17: 1067-1073.
25. Estiasari R, Matsushita T, Masaki K, et al. Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogrens syndrome patients with central nervous system manifestations. Mult Scler 2012; 18: 807-816.
26. Wingerchuk DM and Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012; 18: 5-10.
27. Závada J, Nytrová P, Wandinger KP, et al. Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int 2013; 33: 259-263.
28. Min JH, Kim HJ, Kim BJ, et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: Association with neuromyelitis optica. Mult Scler 2009; 15: 1069-1076.
29. Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica. Brain Pathol 2014; 24: 83-97.
30. Misu T, Höftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125: 815-827.